Thierry Gorlia

Thierry Gorlia

UNVERIFIED PROFILE

Are you Thierry Gorlia?   Register this Author

Register author
Thierry Gorlia

Thierry Gorlia

Publications by authors named "Thierry Gorlia"

Are you Thierry Gorlia?   Register this Author

72Publications

2772Reads

34Profile Views

Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.

Int J Cancer 2020 02 29;146(3):803-809. Epub 2019 Apr 29.

Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Regensburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32337DOI Listing
February 2020

Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.

Neurology 2019 06 10;92(24):e2754-e2763. Epub 2019 May 10.

From the University Medical Center & German Cancer Research Center (M.N., F.S., I.H., P.K., M.P., M.B., W.W.), Heidelberg, Germany; EORTC Headquarters (T.G., V.G.), Brussels, Belgium; Brain Tumor Center at Erasmus MC Cancer Institute (J.E.C.B., W.T., M.J.v.d.B.), Rotterdam, the Netherlands; Medical Oncology Department (A.A.B.), AUSL-Bologna-IRCCS Scienze Neurologiche, Bologna, Italy; Haaglanden Medical Center (M.J.B.T.), the Hague; Leiden University Medical Center (M.J.B.T.), the Netherlands; Institut Gustave Roussy (J.D.), Villejuif; Sorbonne Université (A.I.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris; Institut de Cancerologie de l'Ouest (ICO)-Centre Rene Gauducheau (M.C.), Saint-Herblain, France; Leuven Cancer Institute-KU Leuven (P.M.C.), Belgium; Department of Neurology and Brain Tumor Center (M.W.), University Hospital and University of Zurich, Switzerland; Institut Régional du Cancer Montpellier (M.F.); University of Lille (E.L.R.), U-1192, Inserm; CHU Lille (E.L.R.), General and Stereotaxic Neurosurgery Service; Oscar Lambret Center (E.L.R.), Neurology, Lille, France; Department of Neurology (M.P.), Medical Faculty Mannheim, Heidelberg University, Germany; and Department of Neurology (M.N.), Medical University Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007643DOI Listing
June 2019

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Eur J Cancer 2018 09 20;101:95-104. Epub 2018 Jul 20.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.06.029DOI Listing
September 2018

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

Lancet Oncol 2018 09 13;19(9):1170-1179. Epub 2018 Aug 13.

The Brain and Spine Institute (ICM), Sorbonne Université, The National Institute of Health and Medical Research (INSERM), National Centre for Scientific Research (CNRS), Public Assistance-Paris Hospitals (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183036
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30362-0DOI Listing
September 2018

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

J Neurooncol 2018 May 8;138(1):163-171. Epub 2018 Feb 8.

Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-018-2786-8
Publisher Site
http://dx.doi.org/10.1007/s11060-018-2786-8DOI Listing
May 2018

Farewell to monomodality treatment in patients with WHO lower grade glioma?

Eur J Cancer 2018 01 24;88:109-114. Epub 2017 Nov 24.

EORTC Headquarters, Brain Tumor Group, Avenue Emmanuel Mounier 83/11, 1200 Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.10.019DOI Listing
January 2018

Lomustine and Bevacizumab in Progressive Glioblastoma.

N Engl J Med 2017 11;377(20):1954-1963

From the University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B., M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the Netherlands; the Medical Oncology Department, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.); Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 7225, Sorbonne Universités, University Pierre and Marie Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Épinière, Paris (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-Herblain (M.C.), Institut Régional du Cancer Montpellier, Montpellier (M.F.), and Centre Hospitalier Régional Universitaire de Lille, Lille (E.L.R., F.D.) - all in France; and the Departments of Oncology and Neurology, University Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707358DOI Listing
November 2017

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Neuro Oncol 2017 Aug;19(8):1119-1126

Tel-Aviv Sourasky Medical Center, Tel-Aviv University; European Organization for Research and Treatment of Cancer, Brussels (EORTC); National Institutes of Health (M.R.M.); University of Alabama at Birmingham; Princess Margaret Cancer Centre, University of Toronto; Lausanne University Hospital; NRG Oncology Statistics and Data Management Center; Odette Cancer Centre and Sunnybrook Health Sciences Centre, University of Toronto; Samsung Medical Center, Sungkyunkwan University School of Medicine; Edinburgh Cancer Centre; Mayo Clinic; Robert-Janker Clinic at the University of Bonn Medical Centre, and MAASTRO clinic, GROW School for Oncology, Maastricht University Medical Centre; Miami Cancer Institute; Erasmus University Hospital; Dana-Farber Cancer Institute and Harvard Medical School; University of Zurich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570239PMC
August 2017

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Lancet Oncol 2016 Nov 27;17(11):1533-1542. Epub 2016 Sep 27.

Department of Medical Oncology and Cancer Centre, University Hospital Zurich, Zurich, Switzerland; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC) and GROW (School for Oncology), Maastricht, Netherlands; Department of Radiation-Oncology, MediClin Robert-Janker-Clinic, Clinical Cooperation Unit Neuro-oncology, University Bonn Medical Centre, Bonn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30305-9DOI Listing
November 2016

Corticosteroids compromise survival in glioblastoma.

Brain 2016 05 28;139(Pt 5):1458-71. Epub 2016 Mar 28.

2 Department of Neurosciences at the Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, 44195, USA 3 Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA

View Article

Download full-text PDF

Source
http://brain.oxfordjournals.org/content/brain/early/2016/03/
Web Search
http://pdfs.journals.lww.com/neurosurgery/2016/10000/Do_Cort
Web Search
http://dx.doi.org/10.1093/brain/aww046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006251PMC
May 2016

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.

Neuro Oncol 2016 Mar 9;18(3):388-400. Epub 2015 Sep 9.

Department of Pathology, Rotterdam, the Netherlands (H.J.D., P.N.A., J.M.K., W.N.M.D.); Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands (P.J.F.); Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, Paris, France (M.S., A.I.); Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (P.W.); Department of Pathology, Free University Medical Center, Amsterdam, the Netherlands (P.W.); Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands (R.E.); Department of Pathology, UMCU, Utrecht, the Netherlands (W.S.); Department of Neurology, St. Elisabeth Hospital, Tilburg, the Netherlands (C.T.); European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium (T.G.); Department of Neurology/Neuro-oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (M.J.v.d.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767239PMC
March 2016

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

J Clin Oncol 2016 Mar 19;34(7):731-9. Epub 2016 Jan 19.

Caroline Happold, Patrick Roth, Roger Stupp, and Michael Weller, University Hospital Zurich; Monika Hegi, University Hospital Lausanne, Switzerland; Thierry Gorlia, EORTC Data Centre, Brussels, Belgium; Olivier Chinot, Aix-Marseille University, Marseille, France; Mark R. Gilbert, The University of Texas MD Anderson Cancer Center, Houston, TX; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Wolfgang Wick, University of Heidelberg & German Cancer Research Center, Heidelberg, Germany; Stephanie L. Pugh, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Timothy Cloughesy, UCLA Neuro-Oncology Program, Los Angeles, CA; David A. Reardon, Dana-Farber Cancer Institute, Boston, MA; James R. Perry, University of Toronto, Toronto, Ontario, Canada; and Minesh P. Mehta, University of Maryland, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.6563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070573PMC
March 2016

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

Neuro Oncol 2015 Jul 16;17(7):935-41. Epub 2015 Feb 16.

Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762005PMC
July 2015

Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials.

J Clin Oncol 2015 Jun 27;33(17):1943-50. Epub 2015 Apr 27.

Johan M. Kros and Karin Huizer, Erasmus Medical Center; Pim French and Martin J. van den Bent, Dr Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; Aurelio Hernández-Laín, Hospital Universitario 12 de Octubre Reseach Institute, Madrid; Teresa Ribalta, Hospital Clínic, University of Barcelona, Barcelona, Spain; Gianluca Marucci, Bellaria Hospital, University of Bologna, Bologna; Bianca Pollo, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico "C. Besta," Milano, Italy; Alex Michotte, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel; David Jaminé, Nawal Bekka, Denis Lacombe, and Thierry Gorlia, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Elisabeth J. Rushing, Institute for Neuropathology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0166DOI Listing
June 2015

New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials.

Neuro Oncol 2013 Nov 18;15(11):1568-79. Epub 2013 Sep 18.

Corresponding Author: M. Thierry Gorlia, The European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, 83 Avenue E. Mounier, 1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/not117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813419PMC
November 2013

MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.

Clin Cancer Res 2013 Oct 15;19(19):5513-22. Epub 2013 Aug 15.

Authors' Affiliations: Departments of Neurology, Biostatistics, and Pathology, Neuro-Oncology Unit Erasmus MC, Rotterdam; AP-HP, Groupe Hospitalier Pitie Salpêtrière, Service de Neurologie 2 Mazarin and Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), Paris, France; Department of Pathology, UMCU, Utrecht; Department of Pathology, UMCG, Groningen; Department of Neurology, St. Elisabeth Hospital, Tilburg; Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen; Department of Pathology, Free University Medical Center, Amsterdam, the Netherlands; and European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1157DOI Listing
October 2013

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Clin Cancer Res 2011 Nov 13;17(22):7148-55. Epub 2011 Sep 13.

Neuro-Oncology Unit, Department of Neurology, Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1274DOI Listing
November 2011

Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.

Cancer 2011 Jul 18;117(13):3014-26. Epub 2011 Jan 18.

Mixed Research Unit, UMR 975, INSERM, National Institute of Health and Medical Research-Pierre and Marie Curie University, Pitie-Salpetriere Group Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25827DOI Listing
July 2011

Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.

Int J Radiat Oncol Biol Phys 2010 Jul 14;77(3):670-6. Epub 2009 Oct 14.

Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2009.05.031DOI Listing
July 2010

Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.

Pharmacoeconomics 2002 ;20(7):485-97

European Organization for Research and Treatment of Cancer (EORTC) Data Center, Health Economics Unit, bte. 11, Avenue E. Mounier 83, B-1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00019053-200220070-00006DOI Listing
August 2002